前立腺肥大症（BPH）市場-現状と疫学予測：2033年

G7諸国における良性前立腺肥大症の総有病者数は、2018年から2033年にかけて、0.8%のCAGRで拡大すると予測されています。前立腺肥大症（BPH）は、軽症、中等症、重症のように重症度によって区別されます。2018年、BPHの軽症例は1,400万件、中等症例は2,200万件、重症例は600万件でした。

当レポートは、世界の前立腺肥大症（BPH）市場について調査し、前立腺肥大症の疫学動向、治療法、国別の処方動向などについてまとめています。

目次

良性前立腺肥大症（BPH）- 現状と疫学予測：2033年

良性前立腺肥大症の疫学

エグゼクティブサマリー

良性前立腺肥大症（BPH）疾患の背景

• 疾患の定義
• 症状と原因
• 危険因子
• 病態生理学
• ステージ

良性前立腺肥大症（BPH）の診断

2033年までの疫学予測

• 疫学調査方法と使用したデータソース
  • 米国
  • 英国
  • ドイツ
  • イタリア
  • スペイン
  • フランス
  • 日本

良性前立腺肥大症（BPH）における現在のアンメットニーズ

現在の治療法と医療行為

• 治療と医療行為
• 現在の治療法
  • アルファブロッカー
  • 5α還元酵素阻害剤
  • 併用薬物療法
  • ホスホジエステラーゼ-5酵素阻害剤
  • 治療ガイドライン：アメリカ泌尿器科学会
  • 低侵襲性治療

良性前立腺肥大症（BPH）- 治療アルゴリズム

良性前立腺肥大症の処方パターン

• 米国の処方パターン
• 欧州の処方パターン
• 日本の処方パターン

費用補償と償還プラン

• 米国
• 欧州

Mellalta Meetsについて

お問合せ

Currently, there are a number of drugs approved by the US FDA for benign Prostatic Hyperplasia. For instance, Tadalafil (Eli Lilly), a phosphodiesterase-5 (PDE5) inhibitor approved by the US Food and Drug Administration (FDA) in 2011 to treat benign prostatic hyperplasia (BPH), either alone or in combination with Erectile Dysfunction. Other approved therapies include Proscar (Merck); Avodart (GlaxoSmithKline); Jalyn (GlaxoSmithKline); the approved alpha-blockers include Hytrin (Abbvie), Cardura (Pfizer), Flomax (Astellas), Uroxatral (Sanofi), and Rapaflo (Allergen). Treatment options for benign prostatic hyperplasia may also include lifestyle changes, medications, minimally invasive procedures, and surgery.

Alpha-blockers, 5-alpha reductase inhibitors, and phosphodiesterase-5 inhibitors, among other BPH treatments, are used to treat BPH symptoms by relaxing the smooth bladder muscles or reducing excessive prostate growth. Urine can flow more easily when the bladder muscles are relaxed since this reduces the prostate's hold on the urethra. In contrast, prostate shrinking lessens the pressure the prostate places on the urethra, allowing urine to flow freely.

"BPH treatments are generally effective initially, but as the prostate continues to grow as people get older, there is the possibility of needing additional treatments down the line. TURP has been and probably still is the gold-standard treatment for BPH, but a lot of times, newer procedures can match or beat that effectiveness with fewer side effects and fewer problems."

Benign prostatic hyperplasia (BPH) is a medical condition causing enlargement of the prostate gland. It commonly occurs as men age. BPH is also known as benign prostatic hypertrophy and is a histological diagnosis characterized by the proliferation of cellular elements of the prostate. BPH is considered a normal part of the aging process in men and is hormonally dependent on the production of testosterone and dihydrotestosterone (DHT). It is estimated that 50% of men experience histopathological BPH by age 60. This number increases to 90% by the age of 85.

Benign Prostatic Hyperplasia-Epidemiology

The total prevalent cases of Benign Prostatic Hyperplasia in the G7 countries are projected to increase from 43 million in 2018 to XX million by 2033 with a CAGR of 0.8% for the study period (2018-2033). According to estimates, the United States accounted for the highest prevalence of Benign Prostatic Hyperplasia cases in 2018 which was 14 million cases and is projected to reach XX million cases by 2033 with a CAGR of 1.0 % for the study period. Benign prostatic hyperplasia (BPH) is differentiated as per the severity of the cases as in mild, moderate and severe cases. In 2018, there were 14 million mild; 22 million moderate and 6 million severe cases of the BPH. These cases are expected to increase to XX million mild cases, XX million moderate cases and XX million severe BPH cases in 2033 for the study period from 2018-2033.

Patients do not expect this sickness to improve with treatments because they believe that deteriorating urine symptoms are a natural part of ageing or because they believe that they are only a transitory symptom and do not seek medical help. Whether through industry-funded DTC (direct-to-consumer) marketing or a source that might be less "biased," extensive patient education is required. Men (and those who care for them) need to be aware that untreated BPH can negatively affect general health, perhaps leading to earlier consultation with medical professionals. At least 50% of BPH patients are treated by primary care doctors, who are limited to prescribing drugs to these men. Urologists could have a significant influence by encouraging general practitioners to make earlier referrals.

Report Highlights:

• Benign Prostatic Hyperplasia - Current Market Trends

• Benign Prostatic Hyperplasia - Current & Forecasted Cases across the G7 Countries

• Benign Prostatic Hyperplasia - Untapped Business Opportunities

• Benign Prostatic Hyperplasia - KOLs Insight

Table of Contents

Benign Prostatic Hyperplasia (BPH)- Current Landscape & Epidemiology Forecast 2033

Benign Prostatic Hyperplasia-Epidemiology

• Report Highlights
• Table of Contents

Executive Summary

Benign Prostatic Hyperplasia (BPH) Disease Background

• Disease Definition
• Symptoms & Causes
• Risk Factors
• Pathophysiology
• Stages

Benign Prostatic Hyperplasia (BPH) Diagnosis

Epidemiology Estimated and Forecast to 2033

• Epidemiology Research Method & Data Sources Used
  • United States
    • Prevalent Cases of Benign Prostatic Hyperplasia (BPH)
    • Age-Specific Prevalent Cases of Benign Prostatic Hyperplasia (BPH)
    • Total patients undergoing procedures in the US
  • United Kingdom
    • Prevalent Cases of Benign Prostatic Hyperplasia (BPH)
    • Age-Specific Prevalent Cases of Benign Prostatic Hyperplasia (BPH)
    • Total patients undergoing procedures in the UK
  • Germany
    • Prevalent Cases of Benign Prostatic Hyperplasia (BPH)
    • Age-Specific Prevalent Cases of Benign Prostatic Hyperplasia (BPH)
    • Total patients undergoing procedures in Germany
  • Italy
    • Prevalent Cases of Benign Prostatic Hyperplasia (BPH)
    • Age-Specific Prevalent Cases of Benign Prostatic Hyperplasia (BPH)
    • Total patients undergoing procedures in Italy
  • Spain
    • Prevalent Cases of Benign Prostatic Hyperplasia (BPH)
    • Age-Specific Prevalent Cases of Benign Prostatic Hyperplasia (BPH)
    • Total patients undergoing procedures in Spain
  • France
    • Prevalent Cases of Benign Prostatic Hyperplasia (BPH)
    • Age-Specific Prevalent Cases of Benign Prostatic Hyperplasia (BPH)
    • Total patients undergoing procedures in France
  • Japan
    • Prevalent Cases of Benign Prostatic Hyperplasia (BPH)
    • Age-Specific Prevalent Cases of Benign Prostatic Hyperplasia (BPH)
    • Total patients undergoing procedures in Japan

Current Unmet Needs in Benign Prostatic Hyperplasia (BPH)

Current Treatment & Medical Practices

• Treatment & Medical Practices
• Current Therapies
  • Alpha-Blockers
    • lfuzosin (Uroxatral)
    • Doxazosin (Cardura)
    • Tamsulosin (Flomax)
    • Silodosin (Rapaflo)
  • 5-alpha reductase inhibitors
    • Finasteride (Proscar)
    • Dutasteride (Avodart)
  • Combination drug therapy
    • Dutasteride and tamsulosin hydrochloride (JALYN )
  • Phosphodiesterase-5 Enzyme Inhibitors
    • Tadalafil (CIALIS)
  • Treatment Guidelines: American Urological Association
    • Medical Therapy
    • Surgical Therapy
  • Minimal Invasive Treatments

Benign Prostatic Hyperplasia (BPH)- Treatment Algorithm

Prescription Patterns of Benign Prostatic Hyperplasia

• Prescription Patterns in The United States
• Prescription Patterns in Europe
  • Prescription Patterns in Italy
  • Prescription Patterns in Germany
• Prescription Patterns in Japan

Cost Coverage and Reimbursement plan

• United States
• Europe

About Mellalta Meets

Contact US